Are PCSK9 Inhibitors Ready For “Widespread Use”?
This article was originally published in The Pink Sheet Daily
Executive Summary
Addressing new post hoc analyses of outcomes data, AHA/ACC treatment guidelines chair Neil Stone suggests PCSK9 inhibitors seem on track for an important role in cardiovascular disease, but warns against widespread use until outcomes data from well-powered trials are in.